Analysts' Actions: T, COF, MSFT, LLY, CMG

NEW YORK (TheStreet) -- CHANGE IN RATINGS, EPS

Accretive Health (AH) upgraded at Goldman from Neutral to Buy. $31 price target. Stock is attractive, following a 38% selloff.

Acme Packet (APKT) numbers reduced at Goldman. Shares of APKT now seen reaching $35, according to Goldman Sachs. Estimates also cut, given slower expected revenue growth. Neutral rating.

Alaska Air (ALK) numbers raised at Citigroup. Shares of ALK now seen reaching $81. Estimates also increased leading fundamentals and attractive valuation. Buy rating.

Alaska Air estimates raised at UBS through 2012. Solid 3Q and 2012 cost guidance positive. Maintain $81 price target and Buy rating.

Alexion Pharmaceuticals (ALXN) numbers upped at Jefferies. ALXN estimates were boosted through 2012. Company is seeing higher Soliris sales and cutting costs. Hold rating and new $58 price target.

Alexion Pharmaceutical estimates, target raised at UBS. Shares of ALXN now seen reaching $70. Estimates also increased on aHUS and margins. Neutral rating.

Alliance Data Systems (ADS) upgraded to buy at TheStreet Ratings.

Altera (ALTR) estimates, target reduced at Jefferies. ALTR estimates were cut through 2012. Inventories are falling. Buy rating and new $43 price target.

Altera estimates, target cut at UBS. Shares of ALTR now seen reaching $44.50. Estimates also lowered as weak macro slows secular growth. Buy rating.

Associated Banc-Corp (ASBC) numbers lowered at Jefferies. Shares of ASBC now seen reaching $11. Estimates also cut, given reduced net interest income expectations. Buy rating.

AT&T (T) estimates lowered at Citigroup through 2012. Reflects an elevation in dilution from a rapid adoption of Smartphones. Maintain $32 price target and Buy rating.

AutoNation (AN) estimates, target raised at Goldman. Shares of AN now seen reaching $34. Estimates also increased, given better realized operating margin. Sell rating.

AutoNation estimates lowered at UBS through 2011. Margins tailwinds end post Q3. Maintain $30 price target and Sell rating.

Baxter (BAX) estimates, target reduced at Goldman. BAX estimates were cut through 2014. Lower sales are hurting margins. Buy rating and new $66 price target.

Blackstone (BX) estimates adjusted at Citigroup through 2012. Reflects the 3Q shortfall, but also stronger long term asset gathering outlook. Maintain $18 price target and Buy rating.

Capital One (COF) numbers increased at Goldman through 2013. Higher revenue is driving margin expansion. Neutral rating and new $51 price target.

1 2 3 4 Next › Last »